CD30: CD30 Ligand Interactions in the Immune Response

References

• Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg- Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65–7
   PubMed Web of Science ®Google Scholar
• Ellis T. M., Simms P. E., Slivnick D. J., Jack H. M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993; 151: 2380–9
   PubMed Web of Science ®Google Scholar
• Stein H., Gerdes J., Schwab U., Lemke H., Mason P. Y., Ziegler A., Schienle W., Diehl V. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer 1982; 30: 445–59
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D. Y., Gerdes J., O'Connor N., Wain-Scoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–58
   PubMed Web of Science ®Google Scholar
• Schwarting R., Gerdes J., Durkop H., Falini B., Pileri S., Stein H. BER-H2: a new anti-Ki-l (CD30) monoclonal antibody directed at a formol- resistant epitope. Blood 1989; 74: 1678–89
   PubMed Web of Science ®Google Scholar
• Ito K., Watanabe T., Horie R., Shiota M., Kawamura S., Mori S. High expression of the CD30 molecule in human decidual cells. Am J Pathol 1994; 145: 276–80
   PubMed Web of Science ®Google Scholar
• Mechtersheimer G., Moller P. Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer 1990; 66: 1732–7
   PubMed Web of Science ®Google Scholar
• Pallesen G., Hamilton-Dutoit S. J. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol 1988; 133: 446–50
   PubMed Web of Science ®Google Scholar
• Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421–7
   PubMed Web of Science ®Google Scholar
• Schall T. J., Lewis M., Roller K. J., Lee A., Rice G. C., Wong G. H., Gatanaga T., Granger G. A., Lentz R., Raab H., et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361–70
   PubMed Web of Science ®Google Scholar
• Loetscher H., Pan Y. C., Lahm H. W., Gentz R., Brock-Haus M., Tabuchi H., Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351–9
   PubMed Web of Science ®Google Scholar
• Smith C. A., Davis T., Anderson D., Solam L., Beck-Mann M. P., Jerzy R., Dower S. K., Cosman D., Goodwin R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019–23
   PubMed Web of Science ®Google Scholar
• Gray P. W., Aggarwal B. B., Benton C. V., Bringman T. S., Henzel W. J., Jarrett J. A., Leung D. W., Moffat B., Ng P., Svedersky L. P., et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312: 721–4
   PubMed Web of Science ®Google Scholar
• Pennica D., Nedwin G. E., Hayflick J. S., Seeburg P. H., Derynck R., Palladino M. A., Kohr W. J., Aggarwal B. B., Goeddel D. V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724–9
   PubMed Web of Science ®Google Scholar
• Crowe P. D., Van Arsdale T. L., Walter B. N., Ware C. F., Hession C., Ehrenfels B., Browning J. L., Din W. S., Goodwin R. G., Smith C. A. A lymphotoxin-beta-specific receptor [see comments]. Science 1994; 264: 707–10
   PubMed Web of Science ®Google Scholar
• Browning J. L., Ngam-Ek A., Lawton P., De Marinis J., Tizard R., Chow E. P., Hession C., O'Brine-Greco B., Foley S. F., Ware C. F. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993; 72: 847–56
   PubMed Web of Science ®Google Scholar
• Mallett S., Fossum S., Barclay A. N. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor. EmhoJ 1990; 9: 1063–8
   Google Scholar
• Godfrey W. R., Fagnoni F. F., Harara M. A., Buck D., Engleman E. G. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 1994; 180: 757–62
   PubMed Web of Science ®Google Scholar
• Stamenkovic I., Clark E. A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embo J 1989; 8: 1403–10
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D., Gro L. S., Smaire C, Kullas D., Cha-Lupny N. J., Braesch-Andersen S., Noelle R. J., Stamenkovic I., Ledbetter J. A., Aruffo A. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. Embo J 1992; 11: 4313–21
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–43
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–78
   PubMed Web of Science ®Google Scholar
• Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gur-Ney A. L., Hillan K J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699–703
   PubMed Web of Science ®Google Scholar
• Camerini D., Walz G., Loenen W. A., Borst J., Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147: 3165–9
   PubMed Web of Science ®Google Scholar
• Goodwin R. G., Alderson M. R., Smith C. A., Armit-Age R. J., Vanden Bos T., Jerzy R., Tough T. W., Schoen-Born M. A., Davis-Smith T., Hennen K., et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73: 447–56
   PubMed Web of Science ®Google Scholar
• Smith C. A., Grass H. J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349–60
   PubMed Web of Science ®Google Scholar
• Kwon B. S., Weissman S. M. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989; 86: 1963–7
   PubMed Web of Science ®Google Scholar
• Goodwin R. G., Din W. S., Davis-Smith T., Anderson D. M., Gimpel S. D., Sato T. A., Maliszewski C. R., Brannan C. I., Copeland N. G., Jenkins N. A., et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993; 23: 2631–41
   PubMed Web of Science ®Google Scholar
• Pan G., O'Rourke K., Chinnaiyan A. M., Gentz R., Ebner R., Ni J., Dixit V. M. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–3
   PubMed Web of Science ®Google Scholar
• Tan K. B., Harrop J., Reddy M., Young P., Terrett J., Emery J., Moore G., Truneh A. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35–46
   PubMed Web of Science ®Google Scholar
• Pan G., Ni J., Ywei F., Yu G., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL [see comments]. Science 1997; 277: 815–8
   PubMed Web of Science ®Google Scholar
• Marsters S. A., Sheridan J. R, Pitti R. M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A. D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003–6
   PubMed Web of Science ®Google Scholar
• Anderson D. M., Maraskovsky E., Billingsley W. L., Dougall W. C., Tometsko M. E., Roux E. R., Teepe M. C., DuBose R. F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175–9
   PubMed Web of Science ®Google Scholar
• Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dun-Stan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Cap-Parelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shal-Houb V., Senaldi G., Guo J., Delaney J., Boyle W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76
   PubMed Web of Science ®Google Scholar
• Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H. L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Patti-Son W., Campbell P., Boyle W. J., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. Cell 1997; 89: 309–19
   PubMed Web of Science ®Google Scholar
• Chinnaiyan A. M., O'Rourke K., Yu G. L., Lyons R. H., Garg M., Duan D. R., Xing L., Gentz R., Ni J., Dixit V. M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990–2
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y., Bourdon P R., Xu H., Hsu Y M., Scott H., Hession C., Garcia I., Browning J. L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401–10
   PubMed Web of Science ®Google Scholar
• Hahne M., Kataoka T., Schroter M., Hofmann K., Irm-Ler M., Bodmer J. L., Schneider P., Bornand T., Holler N., French L. E., Sordat B., Rimoldi D., Tschopp J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185–90
   PubMed Web of Science ®Google Scholar
• Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J. L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R. H., Browning J. L., Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747–56
   PubMed Web of Science ®Google Scholar
• Kwon B. S., Tan K. B., Ni J., Oh K. O., Lee Z. H., Kim K. K., Kim Y. J., Wang S., Gentz R., Yu G. L., Harrop J., Lyn S. D., Silverman C., Porter T. G., Truneh A. P, Young R. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997; 272: 14272–6
   PubMed Web of Science ®Google Scholar
• Montgomery R. I., Warner M. S., Lum B. J., Spear P. G. Herpes simplex virus-1 entry into ceils mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427–36
   PubMed Web of Science ®Google Scholar
• Marsters S. A., Ayres T. M., Skubatch M., Gray C. L., Rothe M., Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB andAP- 1. J Biol Chem 1997; 272: 14029–32
   PubMed Web of Science ®Google Scholar
• Mauri D. N., Ebner R., Montgomery R. I., Kochel K. D., Cheung T. C., Yu G. L., Ruben S., Murphy M., Eisen-Berg R. J., Cohen G. H., Spear P. G., Ware C. F. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8: 21–30
   PubMed Web of Science ®Google Scholar
• Johnson D., Lanahan A., Buck C. R., Sehgal A., Morgan C., Mercer E., Bothwell M., Chao M. Expression and structure of the human NGF receptor. Cell 1986; 47: 545–54
   PubMed Web of Science ®Google Scholar
• Laabi Y., Gras M. P., Carbonnel F., Brouet J. C., Berger R., Larsen C. J., Tsapis A. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t (4; 16) (q26;p13) translocation in a malignant T cell lymphoma. Embo J 1992; 11: 3897–904
   PubMed Web of Science ®Google Scholar
• Gurney A. L., Marsters S. A., Huang R. M., Pitti R. M., Mark D. T., Baldwin D. T., Gray A. M., Dowd A. D., Brush A. D., Heldens A. D., Schow A. D., Goddard A. D., Wood W. I., Baker K. P., Godowski P. J., Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999; 9: 215–8
   PubMed Web of Science ®Google Scholar
• Stegh A. H., Schickling O., Ehret A., Scaffidi C., Peter-Hansel C., Hofmann T. G., Grummt I., Krammer P. H., Peter M. E. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. Embo J 1998; 17: 5974–86
   PubMed Web of Science ®Google Scholar
• Pan G., Bauer J. H., Haridas V., Wang S., Liu D., Yu G., Vincenz C., Aggarwal B. B., Ni J., Dixit V. M. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEES Lett 1998; 431: 351–6
   PubMed Web of Science ®Google Scholar
• Horie R., Ito K., Tatewaki M., Nagai M., Aizawa S., Higashihara M., Ishida T., Inoue J., Takizawa H., Watanabe T. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tet-radecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996; 88: 2422–32
   PubMed Web of Science ®Google Scholar
• Horie R., Gattei V., Ito K., Imajo-Ohmi S., Tange T., Miyauchi J., Pinto A., Degan M., DeIuliis A., Tassan Maz-Zocco F., Rossi F. M., Higashihara M., Watanabe T. Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms. Am J Pathol 1999; 155: 2029–41
   PubMed Web of Science ®Google Scholar
• Lee S. Y., Park C. G., Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996; 183: 669–74
   PubMed Web of Science ®Google Scholar
• Amakawa R., Hakem A., Kundig T. M., Matsuyama T., Simard J. J., Timms E., Wakeham A., Mittruecker H. W., Griesscr H., Takimoto H., Schmits R., Shahinian A., Ohashi P., Penninger J. M., Mak T. W. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84: 551–62
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–56
   PubMed Web of Science ®Google Scholar
• Shanebeck K. D., Maliszewski C. R., Kennedy M. K., Picha K. S., Smith C. A., Goodwin R. G., Grabstein K. H. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995; 25: 2147–53
   PubMed Web of Science ®Google Scholar
• Bowen M. A., Olsen K. J., Cheng L., Avila D., Podack E. R. Functional effects of CD30 on a large granular lymphoma cell line, YT Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol 1993; 151: 5896–906
   PubMed Web of Science ®Google Scholar
• McDonald P. P., Cassatella M. A., Bald A., Maggi E., Romagnani S., Gruss H. J., Pizzolo G. CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol 1995; 25: 2870–6
   PubMed Web of Science ®Google Scholar
• Biswas P., Smith C. A., Goletti D., Hardy E. C., Jackson R. W., Fauci A. S. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 1995; 2: 587–96
   PubMed Web of Science ®Google Scholar
• Horie R., Aizawa S., Nagai M., Ito K., Higashihara M., Ishida T., Inoue J., Watanabe T. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol 1998; 10: 203–10
   PubMed Web of Science ®Google Scholar
• Wendtner C. M., Schmitt B., Gruss H. J., Druker B. J., Emmerich B., Goodwin R. G., Hallek M. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res 1995; 55: 4157–61
   PubMed Web of Science ®Google Scholar
• Horie R., Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457–70
   PubMed Web of Science ®Google Scholar
• Baeuerle P. A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141–79
   PubMed Web of Science ®Google Scholar
• Baldwin A. S., Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649–83
   PubMed Web of Science ®Google Scholar
• Ghosh S., May M. J., Kopp E. B. NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225–60
   PubMed Web of Science ®Google Scholar
• Dent P., Jarvis W. D., Birrer M. J., Fisher P. B., Schmidt-Ullrich R. K., Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998; 12: 1843–50
   PubMed Web of Science ®Google Scholar
• English J., Pearson G., Wilsbachcr J., Swantek J., Karandikar M., Xu S., Cobb M. H. New insights into the control of MAP kinase pathways. Exp Cell Res 1999; 253: 255–70
   PubMed Web of Science ®Google Scholar
• Sugawara T., Moriguchi T., Nishida E., Tukuhama Y. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity 1998; 9: 565–74
   PubMed Web of Science ®Google Scholar
• Menitt C., Enslen H., Diehl N., Conze D., Davis R. J., Rincon M. Activation of p38 mitogen-activated protein kinase In vivo selectively induces apoptosis of CD8 (+) but not CD4 (+) T cells [In Process Citation]. Mol Cell Biol 2000; 20: 936–46
   PubMed Web of Science ®Google Scholar
• Gedrich R. W., Gilfillan M. C., Duckett C. S., Van Don-Gen J. L., Thompson C. B. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996; 271: 12852–8
   PubMed Web of Science ®Google Scholar
• Boucher L. M., Marengere L. E., Lu Y, Thukral S., Mak T. W. Binding sites of cytoplasmic effectors TRAFI, 2, and 3 on CD30 and other members ofthe TNF receptor superfamily. Biochem Biophys Res Commun 1997; 233: 592–600
   PubMed Web of Science ®Google Scholar
• Aizawa S., Nakano H., Ishida T., Horie R., Nagai M., Ito K., Yagita H., Okumura K., Inoue J., Watanabe T. Tumor necrosis factor receptor-associated factor (TRAP) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997; 272: 2042–5
   PubMed Web of Science ®Google Scholar
• Devergne O., Hatzivassiliou E., Izumi K. M., Kaye K. M., Kleijnen M. F., Kieff E., Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-iymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996; 16: 7098–108
   PubMed Web of Science ®Google Scholar
• Lee S. Y., Kandala G., Liou M. L., Liou H. C., Choi Y. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Set USA 1996; 93: 9699–703
   PubMed Web of Science ®Google Scholar
• Gravestein L. A., Amsen D., Boes M., Calvo C. R., Kruisbeek A. M., Borst J. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol 1998; 28: 2208–16
   PubMed Web of Science ®Google Scholar
• Duckett C. S., Thompson C. B. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997; 11: 2810–21
   PubMed Web of Science ®Google Scholar
• Lee S. Y., Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 1997; 185: 1275–85
   PubMed Web of Science ®Google Scholar
• Rothe M., Pan M. G., Henzel W. J., Ayres T. M., Goeddel D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apop-tosis proteins. Cell 1995; 83: 1243–52
   PubMed Web of Science ®Google Scholar
• VanArsdale T. L., VanArsdale S. L., Force W. R., Walter B. N., Mosialos G., Kieff E., Reed J. C., Ware C. F. Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci USA 1997; 94: 2460–5
   PubMed Web of Science ®Google Scholar
• Itoh N., Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932–7
   PubMed Web of Science ®Google Scholar
• Tartaglia L. A., Ayres T. M., Wong G. H., Goeddel D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845–53
   PubMed Web of Science ®Google Scholar
• Ashkenazi A., Dixit V. M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255–60
   PubMed Web of Science ®Google Scholar
• Grell M., Zimmermann G., Gottfried E., Chen C M., Grunwald U., Huang D. C., Wu Lee Y. H., Durkop H., Engelmann H., Scheurich P., Wajanl H., Strasser A. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane- anchored TNF. Embo J 1999; 18: 3034–43
   PubMed Web of Science ®Google Scholar
• Pinto A., Aldinucci D., Gloghini A., Zagonel V., Degan M., Improta S., Juzbasic S., Todesco M., Perin V., Gattei V., Herrmann F., Gruss H. J., Carbone A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299–305
   PubMed Web of Science ®Google Scholar
• Younes A., Consoli U., Zhao S., Snell V., Thomas E., Gruss H. J., Cabanillas F., Andreeff M. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 1996; 93: 569–71
   PubMed Web of Science ®Google Scholar
• TadamitsuKishimoto H. K., Kr.v.d Borne A. E.G., Sanna M, Goyert David Mason, Masayuki Miyasaka, Lorenzo Moretta, Okumura Ko, Shaw Stephen, Springer Timothy, Sugamura Kazuo, Zola Heddy. Leucocyte Typing VI. Garland Publishing Inc., New York 1998; Vol. 1: 1320
   Google Scholar
• Gattei V., Degan M., Gloghini A., De A., IuliisImprota S., Rossi F. M., Aldinucci D., Perin V., Serraino D., Babare R., Zagonel V., Gruss H. J., Carbone A., Pinto A. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89: 2048–59
   PubMed Web of Science ®Google Scholar
• Powell I. F., Li T., Jack H. M., Ellis T. M. Construction and expression of a soluble form of human CD30 ligand with functional activity. J Leukoc Biol 1998; 63: 752–7
   PubMed Web of Science ®Google Scholar
• Barner M., Mohrs M., Brombacher F., Kopf M. Differences between 1L-4R alpha-deficient and IL-4-deficient mice reveal a role for 1L-13 in the regulation of Th2 responses. Curr Biol 1998; 8: 669–72
   PubMed Web of Science ®Google Scholar
• Wiley S. R., Goodwin R. G., Smith C. A. Reverse signaling via CD30 ligand. J Immunol 1996; 157: 3635–9
   PubMed Web of Science ®Google Scholar
• Falini B., Pileri S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Schuurman H. J., van Wichen D., de Weger R. A. Expression of activation antigens on thymocytes in the 'common thymocyte' stage of differentiation. Thymus 1989; 14: 43–53
   PubMedGoogle Scholar
• Romagnani P., Annunziato F., Manetti R., Mavilia C., Lasagni L., Manuelli C., Vannelli G. B., Vanini V., Maggi E., Pupilli C., Romagnani S. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 1998; 91: 3323–32
   PubMed Web of Science ®Google Scholar
• Chiarle R., Podda A., Prolla G., Podack E. R., Prolla G., Podack E. R., Thorbecke G. J., Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999; 163: 194–205
   PubMed Web of Science ®Google Scholar
• Heath W. R., Kurts C., Caminschi I., Carbone F. R., Miller J. F. CD30 prevents T-cell responses to non-lymphoid tissues [In Process Citation]. Immunol Rev 1999; 169: 23–9
   PubMed Web of Science ®Google Scholar
• Kurts C., Carbone F. R., Krummel M. F., Koch K. M., Miller J. F., Heath W. R. Signalling through CD30 protects against autoimmune diabetes mediated by CDS T cells. Nature 1999; 398: 341–4
   PubMed Web of Science ®Google Scholar
• Telford W. G., Nam S. Y., Podack E. R., Miller R. A. CD30-regulated apoptosis in murine CDS T cells after cessation of TCR signals. Cell Immunol 1997; 182: 125–36
   PubMed Web of Science ®Google Scholar
• Gilfillan M. C., Noel P. J., Podack E. R., Reiner S. L., Thompson C. B. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998; 160: 2180–7
   PubMed Web of Science ®Google Scholar
• Shimozato O., Takeda K., Yagita H., Okumura K. Expression of CD30 ligand (CD 153) on murine activated T cells. Biochem Biophys Res Commun 1999; 256: 519–26
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Le.uk Lym-phoma 1996; 20: 397–409
   PubMed Web of Science ®Google Scholar
• Bowen M. A., Lee R. K., Miragliotta G., Nam S. Y., Podack E. R. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 1996; 156: 442–9
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Cof R. L. 'fmanTH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–57
   PubMed Web of Science ®Google Scholar
• Del Prete G., DeCarli M., D'Elios M M, Daniel K. C., Almerigogna F., Alderson M., Smith C. A., Thomas E., Romagnani S. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995; 182: 1655–61
   PubMed Web of Science ®Google Scholar
• Del Prete G., De Carli M., Almerigogna F., Daniel C. K., D'Elios M M., Zancuoghi G., Vinante F., Pizzolo G., Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2- type cytokines. Faseb J 1995; 9: 81–6
   PubMed Web of Science ®Google Scholar
• Del Prete G., Maggi E., Pizzolo G., Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995; 16: 76–80
   PubMedGoogle Scholar
• Manetti R., Annunziato F., Biagiotti R., Giudizi M. G., Piccinni M. P., Giannarini L., Sampognaro S., Parronchi P., Vinante F., Pizzolo G., et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994; 180: 2407–11
   PubMed Web of Science ®Google Scholar
• D'Elios M M, Romagnani P., Scaletti C., Annunziato F., Manghetti M, Mavilia C., Parronchi P., Pupilli C., Pizzolo G., Maggi E., Del Prete G. F., Romagnani S. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997; 61: 539–44
   PubMed Web of Science ®Google Scholar
• Vukmanovic-Stejic M., Vyas B., Gorak-Stolinska P., Noble A., Kemeny D. M. Human Tel and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000; 95: 231–40
   PubMed Web of Science ®Google Scholar
• Bengtsson A., Johansson C., Linder M. T., Hallden G., van der Ploeg I., Scheynius A. Not only Th2 cells but also Thl and ThO cells express CD30 after activation. J Leukoc Biol 1995; 58: 683–9
   PubMed Web of Science ®Google Scholar
• Hamann D., Hilkens C M., Grogan J. L., Lens S. M., Kapsenberg M. L., Yazdanbakhsh M., van Lier R. A. CD30 expression does not discriminate between human Thl- and Th2-type T cells. J Immunol 1996; 156: 1387–91
   PubMed Web of Science ®Google Scholar
• Alzona M., Jack H. M., Fisher R. I., Ellis T. M. IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells. J Immunol 1995; 154: 9–16
   PubMed Web of Science ®Google Scholar
• Spinozzi F., Agea E., Piattoni S., Falini B., Grignani F., Bertotto A. Lack of correlation between membrane CD30 expression and cytokine secretion pattern in allergen-primed naive cord blood T-cell lines and clones. Sccmd J Immunol 1997; 45: 417–22
   PubMed Web of Science ®Google Scholar
• Agrawal B., Reddish M., Longenecker B. M. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157: 3229–34
   PubMed Web of Science ®Google Scholar
• Yamaguchi E., de Vries J., Yssel H. Differentiation of human single-positive fetal thymocytes in vitro into IL-4-and/or IFN-gamma-producing CD4+ and CD8+ T cells. Int Immunol 1999; 11: 593–603
   PubMed Web of Science ®Google Scholar
• Scala E., Carbonari M., DelPorto P., Cibati M., Tedesco T., Mazzone A. M., Paganelli R., Fiorilli M. Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. J Immunol 1998; 161: 489–93
   PubMed Web of Science ®Google Scholar
• Munk M. E., Kern P., Kaufmann S. H. Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Int Immunol 1997; 9: 713–20
   PubMed Web of Science ®Google Scholar
• Alzona M., Jack H. M., Fisher R. I., Ellis T. M. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994; 153: 2861–7
   PubMed Web of Science ®Google Scholar
• Martinez O. M., Villanueva J., Abtahi S., Beatty P. R., Esquivel C O., Krams S. M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998; 65: 1240–7
   PubMed Web of Science ®Google Scholar
• Nakamura T., Lee R. K., Nam S. Y, Al-Ramadi B. K., Koni P. A., Bottomly K., Podack E. R., Flavell R. A. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol 1997; 158: 2090–8
   PubMed Web of Science ®Google Scholar
• Annunziato F., Manetti R., Cosmi L., Galli G., Heusser C. H., Romagnani S., Maggi E. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol 1997; 27: 2239–44
   PubMed Web of Science ®Google Scholar
• Vinante E., Krampera M., Morosato L., Rigo A., Romagnani S., Pizzolo G. Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999; 84: 683–9
   PubMed Web of Science ®Google Scholar
• Latza U., Davis S., Wilhelm D., McKnight B., Sey-Farth M., Stein H. Soluble cytokine receptor CD30 in atopic disorders: a case-control study. Clin Exp Allergy 1999; 29: 97–104
   PubMed Web of Science ®Google Scholar
• Caproni M., Bianchi B., D'Elios M. M., De Carli M., Amedei A., Fabbri P. In vivo relevance of CD30 in atopic dermatitis. Allergy 1997; 52: 1063–70
   PubMed Web of Science ®Google Scholar
• De Pita O., Frezzolini A., Cianchini G., Ruffelli M., Teofoli P., Puddu P. T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30). Arch Dermatol Res 1997; 289: 667–70
   PubMed Web of Science ®Google Scholar
• Mavalia C., Scaletti C., Romagnani P., Carossino A. M., Pignone A., Emmi L., Pupilli C., Pizzolo G., Maggi E., Romagnani S. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151: 1751–8
   PubMed Web of Science ®Google Scholar
• Leonard C., Tormey V., Faul J., Burke C M., Poulter L. W. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997; 27: 780–6
   PubMed Web of Science ®Google Scholar
• Jumper M. D., Nishioka Y., Davis L. S., Lipsky P. E., Meek K. Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J Immunol 1995; 155: 2369–78
   PubMed Web of Science ®Google Scholar
• Cerutti A., Schaffer A., Shah S., Zan H., Liou H. C., Goodwin R. G., Casali P. CD30 is a CD40-inducible molecule that negatively regulates CD40- mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity 1998; 9: 247–56
   PubMed Web of Science ®Google Scholar
• Kashii Y., Giorda R., Herberman R. B., Whiteside T. L., Vujanovic N. L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999; 163: 5358–66
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Ulrich D., Dower S. K., Herrmann F., Brach M. A. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor. Blood 1996; 87: 2443–9
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Ulrich D., Braddy S., Armitage R. J., Dower S. K. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Stern-berg cells. Eur J Immunol 1995; 25: 2083–9
   PubMed Web of Science ®Google Scholar
• Stein H., Hummel M. Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies [In Process Citation]. Semin Hematol 1999; 36: 233–41
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic O., Durkop H., Schwarting R., Backe E., Stein H., Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1 -positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19: 157–62
   PubMed Web of Science ®Google Scholar
• Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., Tognellini R., Biagini P., Bertotto A. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102: 547–50
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Bertero M. T., Converso M., Stac-Chini A., Vinante F., Romagnani S., Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2- type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13: 339–43
   PubMed Web of Science ®Google Scholar
• Giacomelli R., Cipriani P., Lattanzio R., Di Franco M., Locanto M., Parzanese I., Passacantando A., Ciocci A., Tonietti G. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997; 108: 42–6
   PubMed Web of Science ®Google Scholar
• Wang G., Hansen H., Tatsis E., Csernok E., Lemke H., Gross W. L. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517–23
   PubMed Web of Science ®Google Scholar
• McMillan S. A., McDonnell G. V., Douglas J. P., Droo-Gan A. G., Hawkins S. A. Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis. Neurology 1998; 51: 1156–60
   PubMed Web of Science ®Google Scholar
• Giacomelli R., Passacantando A., Parzanese L., Vernia P., Klidara N., Cucinelli F., Lattanzio R., Santori E., Cipriani P., Caprilli R., Tonietti G. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). Clin Exp Immunol 1998; 111: 532–5
   PubMed Web of Science ®Google Scholar
• Bottari V., Frezzolini A., Ruffelli M., Puddu P., Fontana L., De Pita O. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999; 54: 507–10
   PubMed Web of Science ®Google Scholar
• Bengtsson A., Holm L., Back O., Fransson J., Scheynius A. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 1997; 109: 533–7
   PubMed Web of Science ®Google Scholar
• Dummer W., Brocker E. B., Bastian B. C. Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. Br J Dermatol 1997; 137: 185–7
   PubMed Web of Science ®Google Scholar
• Frezzolini A., Paradisi M., Ruffelli M., Cadoni S., De Pita O. Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997; 52: 106–9
   PubMed Web of Science ®Google Scholar
• Okumura M., Hidaka Y., Kuroda S., Takeoka K., Tada H., Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997; 82: 1757–60
   PubMed Web of Science ®Google Scholar
• Krams S. M.S. M, Cao S., Hayashi M., ViUanueva J. C., Martinez O. M. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol lmmunopathol 1996; 80: 311–20
   PubMedGoogle Scholar
• Chilosi M., Facchetti F., Notarangelo L. D., Romagnani S., Del Prete G., Almerigogna F., De Carli M., Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol 1996; 26: 329–34
   PubMed Web of Science ®Google Scholar
• Rizzardi G. P., Barcellini W., Tambussi G., Lillo F., Malnati M., Perrin L., Lazzarin A. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. Aids 1996; 10: 45–50
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Vinante F., Morosato L., Nadali G., Chilosi M., Gandini G., Sinicco A., Raiteri R., Semenzato G., Stein H., et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. Aids 1994; 8: 741–5
   PubMed Web of Science ®Google Scholar
• Fattovich G., Vinante F., Giustina G., Morosato L., Alberti A., Ruol A., Pizzolo G. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103: 105–10
   PubMed Web of Science ®Google Scholar
• Vagliasindi C., Spinozzi F., Sensi L., Radicioni M., De Rosa O., Solinas L., Vaccaro R., Bertotto A. Soluble CD30 serum antigen in Kawasaki disease. Acta Paediatr 1997; 86: 317–8
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Pohl C., Berenbeck C., Schroeder J., Jung W., Schmits R., Tschiersch A., Diehl V., Gause A. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. lnt J Cancer 1990; 45: 869–74
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Pileri S., Bendandi M., Buzzi M., Sabat-Tini E., Ascani S., Gherlinzoni F., Magagnoli M., Albertini P., Tura S. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998; 16: 1532–7
   PubMed Web of Science ®Google Scholar
• Nadali G., Vinante F., Stein H., Todeschini G., Tecchio C., Morosato L., Chilosi M., Menestrina F., Kinney M. C., Greer J. P., et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995; 13: 1355–60
   PubMed Web of Science ®Google Scholar
• Gause A., Pohl C., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever D., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983–8
   PubMed Web of Science ®Google Scholar
• Nadali G., Tavecchia L., Zanolin E., Bonfante V., Vivi-Ani S., Camerini E., Musto P., Di Renzo N., Carotenuto M., Chilosi M., Krampera M., Pizzolo G. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011–6
   PubMed Web of Science ®Google Scholar
• Bertotto A., Vagliasindi C., Gerli R., Spinozzi F., Cas-Tellucci G., Fabietti G., Crupi S., Radicioni M., Cozzali R., Ferraro L., Niccoli A., De Rosa O., Lupi C., Brimelli R., Merluzzi A., Guadalupi D., Parente C., Pertici L., Serra M., Vaccaro R. Soluble CD30 antigen in human colostrum. Biol Neonate 1997; 71: 69–74
   PubMedGoogle Scholar
• Maggi E., Annunziato F., Manetti R., Biagiotti R., Giudizi M. G., Ravina A., Almerigogna F., Boiani N., Alder-Son M., Romagnani S. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals. Immunity 1995; 3: 251–5
   PubMed Web of Science ®Google Scholar
• Tsitsikov E. N., Wright D. A., Geha R. S. CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2. Prac Natl Acad Sci USA 1997; 94: 1390–5
   PubMed Web of Science ®Google Scholar
• Price P., Murray R. J., John M., French M. A. High circulating levels of soluble CD30 correlate with impaired delayed- type hypersensitivity responses in HIV-infected patients [letter). Aids 1999; 13: 2308–9
   PubMed Web of Science ®Google Scholar
• Kolb W. P., Granger G. A. Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Pwc Natl Acad Sci US A 1968; 61: 1250–5
   PubMed Web of Science ®Google Scholar